Katrin Neuffer to head Investor & Public Relations at Medios AG

Press release Katrin Neuffer to head Investor & Public Relations at Medios AG Berlin, August 4, 2026 – Medios AG (“Medios”), a leading provider of Specialty Pharma in Europe, has appointed Katrin Neuffer (49) as Director Investor Relations & Communications, effective immediately. In this role, she will be responsible for the Company’s communications with investors, analysts, the media, and the public. She succeeds Claudia Nickolaus, who is handing over leadership of the department to her. Katrin Neuffer holds a degree in business administration and has around 20 years of experience in capital markets communications. After beginning her career at an Investor Relations agency, she was responsible for the Capital Markets and Corporate Communications of SDAX-listed Wacker Neuson SE as Head of Investor Relations & Corporate Communications from 2007 to 2018 – from its IPO through its establishment as a consistently attractive investment. In addition, she led the Strategy and Sustainability departments there. She subsequently headed an international 20-member team as Vice President Investor Relations & Corporate Communications and Marketing at the Exyte Group (formerly M+W Group), where she was responsible for preparing an IPO with a targeted market capitalization of more than €2 billion. Since 2020, she has supported publicly listed companies as an independent consultant in the areas of investor relations, IPO preparation, and crisis and restructuring communications. Claudia Nickolaus played a key role in building and shaping Medios’ Investor Relations activities – from financial reporting and ESG communications to the Company’s first Capital Markets Day in 2022. Prior to joining Medios, she held senior Investor Relations positions at publicly listed companies, including Merck KGaA. Thomas Meier, Chief Executive Officer (CEO) of Medios AG: “With Katrin Neuffer, we are gaining a proven capital markets expert who has guided publicly listed companies through decisive phases of development, from IPOs to strategic repositioning. Her experience will help us reposition Medios in the capital markets and intensify our dialogue with investors, analysts, and the media. On behalf of the Company, I would like to express my sincere thanks to Claudia Nickolaus: Over many years, she shaped Medios’ capital markets communications with tremendous dedication, a high level of professionalism, and personal reliability. She deserves our sincere gratitude for this.” Important events for the Medios Group in the 2026 financial year:

August 12	Half-Year Financial Report 2026
September 21 to 23	Berenberg and Goldman Sachs 15th German Corporate Conference – München
September 28/29	Medios Capital Markets Day
November 10	Quarterly Statement as of September 30, 2026

------------------- About Medios AG
Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the Company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index. www.medios.group More information on individualized medicine: https://app.medios.group/en/individualizedmedicine   Contact
Claudia Nickolaus
Head of Investor & Public Relations
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.ag